Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A distinct immunophenotype identifies a subset of NPM1-mutated AML with TET2 or IDH1/2 mutations and improved outcome.

American journal of hematology - 1 Aug 2018

Mason Emily F, Kuo Frank C, Hasserjian Robert P, Seegmiller Adam C, Pozdnyakova Olga

Abstract excerpt

Recent work has identified distinct molecular subgroups of acute myeloid leukemia (AML) with implications for disease classification and prognosis. NPM1 is one of the most common recurrently mutated genes in AML. NPM1 mutations often co-occur with FLT3-ITDs and mutations in genes regulating DNA methylation, such as DNMT3A, TET2, and IDH1/2. It remains unclear whether these genetic alterations are associated with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Dioxygenases
Share to Disease-Free Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunophenotyping

Share to Isocitrate Dehydrogenase

Share to Kaplan-Meier Estimate

Share to Leukemia, Myeloid, Acute

Share to Neoplasm Proteins

Share to Nucleophosmin

Source

Identifiers

PMID: 29274134
DOI: 10.1002/ajh.25018

Genes

NPM1
IDH1
TET2
FLT3
IDH2
PML
RARA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A distinct immunophenotype identifies a subset of NPM1-mutated AML with TET2 or IDH1/2 mutations and improved outcome.PMID 29274134Read ↗

Blast phenotype and comutations in acute myeloid leukemia with mutated NPM1 influence disease biology and outcome.Semantic proximity Read ↗

TET2 gene mutation is unfavorable prognostic factor in cytogenetically normal acute myeloid leukemia patients with NPM1+ and FLT3-ITD - mutations.Semantic proximity Read ↗

Subtype-specific patterns of molecular mutations in acute myeloid leukemia.Semantic proximity Read ↗

The combination of NPM1, DNMT3A, and IDH1/2 mutations leads to inferior overall survival in AMLSemantic proximity Read ↗

Overlapping features of therapy-related and de novo NPM1-mutated AML.Semantic proximity Read ↗

Acute myeloid leukemia with mutated NPM1 mimics acute promyelocytic leukemia presentation.Semantic proximity Read ↗

Myeloid sarcoma with NPM1 mutation may be clinically and genetically distinct from AML with NPM1 mutation: a study from the Bone Marrow Pathology Group.Semantic proximity Read ↗

Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML.Semantic proximity Read ↗

Biological and therapeutic implications of a unique subtype of NPM1 mutated AML.Semantic proximity Read ↗

High NPM1 mutant allele burden at diagnosis correlates with minimal residual disease at first remission in de novo acute myeloid leukemiaSemantic proximity Read ↗

Influence of genetic co-mutation on chemotherapeutic outcome in NPM1-mutated and FLT3-ITD wild-type AML patients.Semantic proximity Read ↗

AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.